IPO Details
- Open Date 16-Dec-21
- Close Date 20-Dec-21
- Lot Size 54
- IPO Size ₹ 700 Cr
- IPO Price Range ₹ 265 to ₹274
- Min Investment ₹ 14,310
- Listing Exchange NSE, BSE
- Basis of Allotment 23-Dec-21
- Refunds 24-Dec-21
- Credit to Demat Account 27-Dec-21
- Listing Date 28-Dec-21
Supriya Lifescience Ltd IPO Subscription Status
| Category | Subscription Status |
| Qualified Institutional (QIB) | 31.83 Times |
| Non-Institutional (NII) | 161.22 Times |
| Retail Individual | 55.76 Times |
| Total | 71.47 Times |
Supriya Lifescience IPO Subscription Details (Day by Day)
| Date | QIB | NII | Retail | Total |
| December 16, 2021 17:00 | 0.00x | 0.66x | 11.84x | 2.33x |
| December 17, 2021 17:00 | 0.53x | 2.90x | 25.38x | 5.69x |
| December 20, 2021 17:00 | 31.83x | 161.22x | 55.76x | 71.47x |
IPO Synopsis
The active pharmaceuticals manufacturer, Supriya Lifescience Ltd will open its issue for subscription between December 16 and December 20. The company will be listed on the stock exchange on December 28, 2021. The price band for the issue is Rs.265-274 per share with the minimum investment being Rs.14,796 (54 shares * Rs.274).
The issue consists of a fresh issue worth Rs.200 crore and an offer for sale worth Rs.500 crore by Satish Waman Wagh, making the total issue worth Rs.700 crore. The promoter holds a stake of 99.98% stake in the company. The book running lead managers to the issue are ICICI Securities Ltd and Axis Capital Ltd.
Objectives of the issue:
1. Rs.85.38 crore from the net proceeds of the issue is to be used to fund capital expenditure requirements of the company
2. Rs.67 crore is to be used for the repayment and prepayment of debt availed by the company
About Supriya Lifescience Ltd
Supriya Lifescience, founded in 1987, is one of the key manufacturers and suppliers of active pharmaceutical ingredients (APIs). The company offers 39 APIs which are focused on diverse therapeutic segments like antihistamine, vitamin, anesthetic, anti-asthmatic and anti-allergic. The company is the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride. These account for 45-55% and 65-70% of the exports of API exports of the country between FY17-FY20. In FY20, Supriya Lifescience was one of the largest exporters of Salbutamol Sulphate, in terms of volume.
In FY21, the company exported its products to 78 countries, 1,060 customers, including 286 distributors. Supriya Lifescience has expanded their API business to Europe, Latin America and North America. Their customers include Syntec Do Brasil LTDA, American International Chemical Inc, AT Planejamento E Desenbolvimento De Negocios Ltda, Mankind Pharma Ltd etc.
The company has a manufacturing facility in Maharashtra which is spread across 23,806 sq mts. They also operate 5 cleanrooms and are in the process of setting up 2 more new cleanrooms. These 7 are going to be commercialized in FY22. The manufacturing facility of Supriya Lifescience has received approvals from USFDA, EDQM TGA- Australia, KFDA- Korea, PMDA Japan, NMPA- China and Health Canada.
Supriya Lifescience Ltd Financial Status
|
Particulars (In Rs cr) |
FY21 |
Q3 ended 31 December, 2020 |
FY20 |
FY19 |
|
Revenue from operations |
396.22 |
255.71 |
311.64 |
277.84 |
|
PAT |
123.83 |
76.18 |
73.37 |
39.42 |
|
EPS (In Rs) |
- |
10.41 |
10.03 |
5.39 |
|
Particulars (In Rs cr) |
Q3 ended 31 December, 2020 |
FY20 |
FY19 |
|
Total Assets |
196.16 |
336.40 |
253.05 |
|
Total Borrowings |
58.43 |
82.21 |
89.83 |
|
Equity Share Capital |
14.63 |
14.63 |
14.63 |
|
Asset turnover |
2.73 |
3.33 |
3.41 |
|
Debt to Equity ratio |
0.25 |
0.55 |
0.95 |
Key Ratios
|
Particulars
|
Q3 ended 31 December, 2020 |
FY20 |
FY19 |
FY18 |
|
Gross Margin |
63.15% |
55.56% |
47.14% |
36.36% |
|
EBITDA % |
42.87% |
33.92% |
25.45% |
13.79% |
|
Profit Margin |
28.44% |
22.74% |
13.79% |
3.94% |
|
Current ratio |
1.69 |
1.26 |
0.98 |
0.82 |
Key Points for Supriya Lifesciences IPO are :
IPO Key Points
-
Strengths:
1. The company has a significant leadership in the niche and key products market. They are the largest exporters of Chlorpheniramine Maleate and Ketamine Hydrochloride
2. Supriya Lifescience Ltd uses a backward integration model. As of now, 11 of their products, which account for 63.25% of the revenue, are backward integrated
3. The company has an added advantage of a high geographical diversification as they are spread across 78 countries across the globe
4. Supriya Lifescience Ltd has a very experienced and skillful operational personnel as well as experienced senior management and promoters -
Risks:
1. If the company does not develop new products in time or the already commercialized products are not very well received in the market, it will adversely affect the financials of the company
2. A manufacturing or quality control problem will negatively affect the reputation of the company, thus decreasing the goodwill among the customers
3. A significant amount of revenue is derived from a few specific products and if the demand for these products decrease, this will materially affect the business of the company
4. Failure to achieve optimal capital utilization or a shutdown or disruption in production will adversely affect the operations of the business
How to apply for IPO?
-
Login to your 5paisa account and select the issue in the
current IPO section -
Enter the number of lots and price at which you wish to
apply for -
Enter your UPI ID and click on submit. With this, your
bid will be placed with the exchange -
You will receive a mandate notification to block funds in
your UPI app -
Approve the mandate request on your UPI and funds
will be blocked
Open account in 5 minutes
Be a part of the 5paisa community now with 10 million mobile app users
IPO FAQs
What is the issue size of Supriya Lifescience IPO?
The issue size is around Rs.700 crore.
What is the maximum number of shares of the Supriya Lifescience IPO that I can apply for?
The maximum is 13 lots- 702 shares, worth Rs.1,92,348.
How many shares will I get in 1 lot?
1 lot of Supriya Lifescience IPO has 54 shares.
When will the share be listed on the stock exchanges?
On December 28 th, 2021, Supriya Lifescience Ltd will be listed on the stock exchanges.
Where is Supriya Lifescience IPO going to be listed?
NSE and BSE both.
What is the price of each share going to be?
The price band set for each share of Supriya Lifescience Ltd, is Rs.265-Rs.274 per share.
Who is the registrar to the offer?
Link Intime India Pvt Ltd is the registrar to the Supriya Lifescience IPO.
What is the pre issue shareholding of the promoters of Supriya Lifescience Ltd?
The pre issue shareholding will stand at 99.98%.
How do I check the allotment status?
Way to check 1- First you need to go to the registrar’s site- Link Intime India Pvt Ltd and then visit the IPO allotment page. From the drop down menu, select Supriya Lifescience Ltd. Then, enter your PAN card details and select the application type- ASBA or Non-ASBA and enter the required details. After this the status is displayed on the screen.
Way to check 2- Visit the BSE application website page, select equity and then select Supriya Lifescience Ltd from the drop down menu. After entering your PAN card details and application number, the status is displayed on the screen.
What is the minimum investment required?
The minimum investment required to apply for the Supriya Lifescience Ltd IPO is Rs.14,796.
It is the upper range of the IPO price i.e. Rs.274*54 shares (1 lot). Minimum investment in an IPO is the amount of money that you need to invest in order to receive 1 lot of shares of the IPO. The number of shares in 1 lot varies from IPO to IPO but normally, the minimum investment value is calculated by multiplying the number of shares in 1 lot with the upper price range of the IPO price per share.
Contact Details of Supriya Lifescience Ltd IPO
Contact Information
Supriya Lifescience Limited
207/208, Udyog Bhavan,
Sonawala Road, Goregaon,
East, Mumbai – 400063, Maharashtra, India
Phone: +91-22-40332727
Email: cs@supriyalifescience.com
Website: https://supriyalifescience.com/
Supriya Lifescience Ltd IPO Register
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: supriyalife.ipo@linkintime.co.in
Website: https://linkintime.co.in/
Supriya Lifescience Ltd IPO Lead Manager
Axis Capital Limited
ICICI Securities Limited